LCM
OCUL icon

Lynwood Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Lynwood Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-262,500
Closed -$1.35M – 102
2023
Q2 		$1.35M Buy
+262,500
New +$1.56M 1.72% 16

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Lynwood Capital Management's OCUL Position: Q3 2023 in Review

Lynwood Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2023, closing a stake of 262,500 shares — an estimated $1.35M sold.

Lynwood Capital Management first reported a position in OCUL in Q2 2023 and held it in 1 quarter. The position peaked at $1.35M in Q2 2023. 113 funds tracked by Wall St. Rank hold OCUL as of Q3 2023.

  • Lynwood Capital Management reported no remaining Ocular Therapeutix position as of Q3 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 262,500 Ocular Therapeutix shares in Q3 2023, an estimated $1.35M.
  • Lynwood Capital Management first reported a position in Ocular Therapeutix in Q2 2023 and held it in 1 quarter.
  • Lynwood Capital Management's Ocular Therapeutix position peaked at $1.35M in Q2 2023.
  • 113 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2023.

Based on Lynwood Capital Management's 13F filing for Q3 2023, filed 1 Nov 2023.